- Home
- PRAX vs COLL Comparison
PRAX vs COLL Comparison
Compare PRAX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- COLL
- Stock Information
- Founded
- PRAX 2015
- COLL 2002
- Country
- PRAX United States
- COLL United States
- Employees
- PRAX N/A
- COLL N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- COLL Health Care
- Exchange
- PRAX Nasdaq
- COLL Nasdaq
- Market Cap
- PRAX 952.1M
- COLL 958.8M
- IPO Year
- PRAX 2020
- COLL 2015
- Fundamental
- Price
- PRAX $52.00
- COLL $33.37
- Analyst Decision
- PRAX Strong Buy
- COLL Strong Buy
- Analyst Count
- PRAX 10
- COLL 4
- Target Price
- PRAX $93.30
- COLL $44.25
- AVG Volume (30 Days)
- PRAX 435.3K
- COLL 401.3K
- Earning Date
- PRAX 11-05-2025
- COLL 11-06-2025
- Dividend Yield
- PRAX N/A
- COLL N/A
- EPS Growth
- PRAX N/A
- COLL N/A
- EPS
- PRAX N/A
- COLL 1.06
- Revenue
- PRAX $7,765,000.00
- COLL $707,007,000.00
- Revenue This Year
- PRAX N/A
- COLL $22.23
- Revenue Next Year
- PRAX $20.00
- COLL $2.78
- P/E Ratio
- PRAX N/A
- COLL $31.62
- Revenue Growth
- PRAX 338.45
- COLL 22.61
- 52 Week Low
- PRAX $26.70
- COLL $23.23
- 52 Week High
- PRAX $91.83
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- PRAX 56.68
- COLL 36.46
- Support Level
- PRAX $46.99
- COLL $34.19
- Resistance Level
- PRAX $55.86
- COLL $35.83
- Average True Range (ATR)
- PRAX 3.62
- COLL 1.03
- MACD
- PRAX 0.56
- COLL -0.29
- Stochastic Oscillator
- PRAX 74.41
- COLL 6.56
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.